Together Pharma Statistics
Total Valuation
Together Pharma has a market cap or net worth of ILS 62.85 million. The enterprise value is 105.95 million.
Market Cap | 62.85M |
Enterprise Value | 105.95M |
Important Dates
The next estimated earnings date is Thursday, November 27, 2025.
Earnings Date | Nov 27, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Together Pharma has 17.35 million shares outstanding. The number of shares has increased by 41.07% in one year.
Current Share Class | 17.35M |
Shares Outstanding | 17.35M |
Shares Change (YoY) | +41.07% |
Shares Change (QoQ) | +3.44% |
Owned by Insiders (%) | 75.15% |
Owned by Institutions (%) | 0.00% |
Float | 4.31M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.58 |
PB Ratio | 1.27 |
P/TBV Ratio | 3.01 |
P/FCF Ratio | 6.82 |
P/OCF Ratio | 6.49 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.45, with an EV/FCF ratio of 11.50.
EV / Earnings | -16.15 |
EV / Sales | 0.97 |
EV / EBITDA | 14.45 |
EV / EBIT | 282.53 |
EV / FCF | 11.50 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 1.01.
Current Ratio | 1.11 |
Quick Ratio | 0.43 |
Debt / Equity | 1.01 |
Debt / EBITDA | 6.80 |
Debt / FCF | 5.41 |
Interest Coverage | 0.05 |
Financial Efficiency
Return on equity (ROE) is -14.88% and return on invested capital (ROIC) is 0.23%.
Return on Equity (ROE) | -14.88% |
Return on Assets (ROA) | 0.15% |
Return on Invested Capital (ROIC) | 0.23% |
Return on Capital Employed (ROCE) | 0.52% |
Revenue Per Employee | 548,834 |
Profits Per Employee | -32,975 |
Employee Count | 199 |
Asset Turnover | 0.71 |
Inventory Turnover | 1.54 |
Taxes
Income Tax | -975,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.43% in the last 52 weeks. The beta is 0.36, so Together Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.36 |
52-Week Price Change | -7.43% |
50-Day Moving Average | 383.91 |
200-Day Moving Average | 411.19 |
Relative Strength Index (RSI) | 43.02 |
Average Volume (20 Days) | 8,314 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Together Pharma had revenue of ILS 109.22 million and -6.56 million in losses. Loss per share was -0.51.
Revenue | 109.22M |
Gross Profit | 17.12M |
Operating Income | 375,000 |
Pretax Income | -8.20M |
Net Income | -6.56M |
EBITDA | 6.16M |
EBIT | 375,000 |
Loss Per Share | -0.51 |
Balance Sheet
The company has 9.56 million in cash and 49.87 million in debt, giving a net cash position of -40.31 million or -2.32 per share.
Cash & Cash Equivalents | 9.56M |
Total Debt | 49.87M |
Net Cash | -40.31M |
Net Cash Per Share | -2.32 |
Equity (Book Value) | 49.57M |
Book Value Per Share | 3.28 |
Working Capital | 8.62M |
Cash Flow
In the last 12 months, operating cash flow was 9.69 million and capital expenditures -473,000, giving a free cash flow of 9.21 million.
Operating Cash Flow | 9.69M |
Capital Expenditures | -473,000 |
Free Cash Flow | 9.21M |
FCF Per Share | 0.53 |
Margins
Gross margin is 15.67%, with operating and profit margins of 0.34% and -6.01%.
Gross Margin | 15.67% |
Operating Margin | 0.34% |
Pretax Margin | -7.51% |
Profit Margin | -6.01% |
EBITDA Margin | 5.64% |
EBIT Margin | 0.34% |
FCF Margin | 8.44% |
Dividends & Yields
Together Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -41.07% |
Shareholder Yield | n/a |
Earnings Yield | -10.44% |
FCF Yield | 14.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on August 13, 2023. It was a reverse split with a ratio of 0.1.
Last Split Date | Aug 13, 2023 |
Split Type | Reverse |
Split Ratio | 0.1 |
Scores
Together Pharma has an Altman Z-Score of -0.81 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.81 |
Piotroski F-Score | 5 |